Curis, Inc.  

(Public, NASDAQ:CRIS)   Watch this stock  
Find more results for CRIS
1.37
-0.02 (-1.44%)
Oct 22 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 1.34 - 1.40
52 week 1.19 - 4.59
Open 1.39
Vol / Avg. 0.00/386,444.00
Mkt cap 119.55M
P/E     -
Div/yield     -
EPS -0.16
Shares 86.00M
Beta 2.26
Inst. own 49%
Nov 18, 2014
Curis Inc at Stifel Healthcare Conference Add to calendar
Nov 10, 2014
Curis Inc Extraordinary Shareholders Meeting - 12:00PM EST - Add to calendar
Nov 3, 2014
Q3 2014 Curis Inc Earnings Release-Tentative Add to calendar
Oct 7, 2014
Curis Inc at BIO Investor Forum
Sep 10, 2014
Curis Inc at Rodman & Renshaw Global Investment Conference
Sep 3, 2014
Curis Inc at Robert W. Baird & Co. Inc Health Care Conference
Aug 7, 2014
Q2 2014 Curis Inc Earnings Release
Aug 7, 2014
Q2 2014 Curis Inc Earnings Call
More events from DailyFinance »    

Key stats and ratios

Q2 (Jun '14) 2013
Net profit margin -39.49% -82.14%
Operating margin -32.17% -62.77%
EBITD margin - -61.82%
Return on average assets -10.19% -16.39%
Return on average equity -19.02% -31.02%
Employees 33 -
CDP Score - -

Address

4 Maguire Road
LEXINGTON, MA 02421
United States - Map
+1-617-5036500 (Phone)
+1-617-5036501 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Curis, Inc. is a drug discovery and development company that is committed to leveraging signaling pathway drug technologies in seeking to develop next generation network-targeted cancer therapies. The Company conducts its research and development programs both internally and through strategic collaborations. Its advanced program is Hedgehog pathway inhibitor program under collaboration with Genentech, Inc., a wholly owned member of the Roche Group. The lead drug candidate being developed under this program is Erivedge, a orally-administered small molecule Hedgehog pathway inhibitor, which is also known as vismodegib, GDC-0449 and RG3616. In October 2011, the Company completed a Phase Ib expansion trial to test CUDC-101. The Company�s other development candidate under collaboration is Debio 0932 (formerly CUDC-305).

Officers and directors

James R. McNab Jr. Independent Chairman of the Board
Age: 70
Bio & Compensation  - Reuters
Ali Fattaey Ph.D. President, Chief Executive Officer, Director
Age: 49
Bio & Compensation  - Reuters
Daniel R. Passeri J.D. Vice Chairman of the Board
Age: 53
Bio & Compensation  - Reuters
Michael P. Gray Chief Financial Officer
Age: 43
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Jaye Viner M.D. Chief Medical Officer, Executive Vice President
Age: 57
Bio & Compensation  - Reuters
Mani Mohindru Ph.D. Vice President - Corporate Strategy and Investor Relations
Bio & Compensation  - Reuters
Tania Chander Pharm.D. Vice President - Product Development
Bio & Compensation  - Reuters
Mark W. Noel Vice President - Technology Management and Intellectual Property
Age: 54
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Kenneth J. Pienta M.D. Director
Age: 53
Bio & Compensation  - Reuters
Martyn D. Greenacre Independent Director
Age: 72
Bio & Compensation  - Reuters